Asset Details
Do you wish to reserve the book?
Cardioprotection by direct factor Xa inhibition in angiotensin II overexpression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cardioprotection by direct factor Xa inhibition in angiotensin II overexpression
Do you wish to request the book?
Cardioprotection by direct factor Xa inhibition in angiotensin II overexpression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cardioprotection by direct factor Xa inhibition in angiotensin II overexpression
2021
Overview
Direct factor Xa (FXa) inhibitors have been used as active oral anticoagulant agents to prevent stroke and deep vein thrombosis. Recently, the anti-inflammatory effects of FXa inhibitors have been expected to reduce the risk of future cardiovascular events via its effect on various signaling pathways through activation of protease-activated receptors (PARs) and non-PARs [1]. PARs are seven-transmembrane domain receptors that are activated by the specific proteolytic cleavage of the N-terminal extracellular domain by endogenous serine proteases, such as thrombin (which acts on PAR-1, -3, and -4) and trypsin, tryptase, factor VIIa, and FXa (which act on PAR-2), and the released N-terminal tail binds the receptor itself and induces intracellular signaling [2].
Publisher
Springer Science and Business Media LLC,Nature Publishing Group
